Kwan Pui San 4

4 · ChemoCentryx, Inc. · Filed Mar 1, 2021

Form 4

Period: 2021-02-25

Principal Acctg Officer

Transactions

Award
Stock Option (right to buy)
2021-02-25+16,640→ 16,640 total
Exercise: $65.87Exp: 2031-02-25→ Common Stock (16,640 underlying)
Exercise/Conversion
Common Stock
2021-03-01$9.04/sh+833$7,530→ 6,579 total
Exercise/Conversion
Common Stock
2021-03-01$10.86/sh+1,389$15,085→ 4,621 total
Exercise/Conversion
Common Stock
2021-03-01$11.02/sh+1,125$12,398→ 5,746 total
Sale
Common Stock
2021-03-01$68.08/sh−1,530$104,169→ 5,049 total
Exercise/Conversion
Stock Option (right to buy)
2021-03-01−1,389→ 13,897 total
Exercise: $10.86Exp: 2028-03-05→ Common Stock (1,389 underlying)
Sale
Common Stock
2021-03-01$68.89/sh−1,817$125,166→ 3,232 total
Exercise/Conversion
Stock Option (right to buy)
2021-03-01−1,125→ 24,750 total
Exercise: $11.02Exp: 2029-03-04→ Common Stock (1,125 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-03-01−833→ 25,834 total
Exercise: $9.04Exp: 2029-11-01→ Common Stock (833 underlying)

Footnotes (6)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
[F2]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $67.64 to $68.60 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
[F3]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $68.64 to $69.19 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
[F4]The option was granted on February 25, 2021, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2022, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date.
[F5]Not applicable.
[F6]As of March 1, 2021, and prior to this transaction, the exercised options were fully vested.

Documents

1 file